NCT02035020CompletedPhase 2
A Phase IIa Clinical Trial to Test the Safety and Efficacy of Interferon Gamma Treatment in Elevating Frataxin Levels in Friedreich's Ataxia (FRDA) Patients
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Change in cellular frataxin
Study Overview
Brief Summary
The primary objective of this study is to investigate whether the treatment with IFN gamma can induce significant accumulation of frataxin in FRDA patients, a possibility suggested by pre-clinical evidence in an animal model of the disease.
Detailed Description
This is a Phase 2 clinical trial. A total of 10 FRDA patients will be recruited All subjects will be treated with a dose of 100-150-200-micrograms of IFN gamma 1b (Imukin®) subcutaneously, with an interval of 14 days, for a total of 3 injections.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •FRDA patients should have their diagnosis genetically confirmed.
- •Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- •Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •Male and/or female subjects between the ages of > 18 and < 45 years
Exclusion Criteria
- •Pregnant or breastfeeding women.
- •Significant concurrent medical conditions at the time of screening or baseline visit, including, but not limited to, the following:
- •Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, GI, endocrine, pulmonary, immunologic, or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.
- •Class III or IV congestive heart failure as defined by the New York Heart Association.
- •Acute coronary syndrome (eg, myocardial infarction, unstable angina pectoris) and any history of significant cerebrovascular disease within 24 weeks before screening.
- •Presence of a transplanted organ.
- •Previous assumption of IFN gamma 1b.
- •Abnormality in any of the below hematology or chemistry profile values at screening:
- •Positive hepatitis B surface antigen (HBsAg), Total hepatitis B core antibody (HBcAb; also called anti HBc), and/or hepatitis C antibody (HCVAb) with confirmation by hepatitis C virus ribonucleic acid (HCV RNA).
- •ALT/AST levels > or = 1.5X ULN.
- •Total bilirubin level > or = 1.5 times the ULN.
- •Hemoglobin level < or = 80 gL (8.0 g/dL).
- •Platelet count < or = 100 x 109/L (100,000 cells/mm³) or > or = 1000 x 109/L (1,000,000 cells/mm³).
- •White blood cell count < or = 3.5 x 109/L (3500 cells/mm³).
- •Absolute neutrophil count (ANC) <2000 cells/mm³.
- •Serum creatinine level > or = 177 μmol/ L (2 mg/dL).
- •Glycosylated hemoglobin (HbA1c >10%).
- •Current or history of serious psychiatric disorder or alcohol or drug abuse.
- •Participation in other studies within 30 days before screening and/or during study participation.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or ability to comply with study procedures, investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Arms & Interventions
Gamma interferon
Experimental
IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
Intervention: gamma interferon (Drug)
Outcomes
Primary Outcomes
Change in cellular frataxin
Time Frame: 24 hours and 7 days from each study drug administration
The primary endpoint is to test the increase of cellular frataxin after treatment with IFN gamma. Quantitation of cellular frataxin will be performed after 24 hours and 7 days from each study drug administration
Secondary Outcomes
- Safety Blood sample(day 0-14-28-35)
Investigators
Carlo Casali
Professor
Azienda Policlinico Umberto I
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and TuberculosisHIV CoinfectionAids/Hiv ProblemTuberculosis, PulmonaryHuman Immunodeficiency VirusLentivirus InfectionsRNA Virus InfectionsNCT05065905SPP Pharmaclon Ltd.78
Completed
Phase 1
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast CancerBreast Cancer, MaleBreast Cancer FemaleBreast CancerHER2-positive Breast CancerNCT03112590H. Lee Moffitt Cancer Center and Research Institute51
Recruiting
Phase 2
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell TransplantationMyelodysplastic SyndromesAcute Myeloid LeukemiaNCT06529731Sawa Ito, MD57
Completed
Phase 2
Open Trail of γIFN for Friedreich AtaxiaFriedreich AtaxiaNCT03888664IRCCS Eugenio Medea12
Completed
Phase 3
A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisNCT00047645InterMune330